Pharma Mar SA (0RC6) Share Price & Analysis
0RC6 Stock Chart & Stats
- Day’s Range
- EUR 66.10 - EUR 69.45
- 52-Week Range
- EUR 63.60 - EUR 105.40
- Previous Close
- EUR 69.05
- Volume
- 1,530
- Average Volume (3M)
- 1,796
- Market Cap
- EUR 1.20B
- Enterprise Value
- EUR 1.18B
- Total Cash (Recent Filing)
- EUR 168.88M
- Total Debt (Recent Filing)
- EUR 45.84M
- Price to Earnings (P/E)
- 20.7
- Beta
- 0.41
- Next Earnings
- Mar 01, 2027 (Est.)
- EPS Estimate
- 0.98
- Last Dividend Ex-Date
- Jul 08, 2026
- Dividend Yield
- 1.47%
Bulls Say, Bears Say
Bulls Say
High Profitability And Margins
Very high gross and net margins indicate that Pharma Mar’s approved oncology portfolio generates substantial economic value relative to revenue. If maintained, this profitability provides resources for research, commercialization, and partnerships while supporting resilience across the next several quarters.
Conservative Balance Sheet
Low leverage and a substantial equity base give Pharma Mar financial flexibility to fund development and commercial activities without relying heavily on debt. This reduces balance-sheet pressure and improves its ability to absorb operating volatility over the medium term.
Positive Recent Cash Generation
Recent operating and free cash flow show that reported earnings are converting into cash at a generally healthy rate. That supports internally funded investment, strengthens liquidity, and gives the company greater capacity to sustain oncology development and commercial operations.
Bears Say
Inconsistent Revenue Growth
The latest revenue decline shows that commercial growth has not been consistently sustained despite the 2025 rebound. Uneven top-line performance can make future earnings less predictable and may limit the pace at which Pharma Mar can expand its operating base.
Volatile Cash Generation
Although the latest period produced positive free cash flow, the prior negative years and current 11.5% decline demonstrate that cash generation can fluctuate materially. This may complicate long-term planning and reduce certainty around internally funded investment.
Earnings And Returns Volatility
The sharp swings in net income, including negative EBIT in 2023 and subsequent moderation from 2025, indicate that profitability is sensitive to operating conditions. Such variability makes sustainable earnings power harder to assess and increases medium-term execution risk.
0RC6 FAQ
What was Pharma Mar SA’s price range in the past 12 months?
What is Pharma Mar SA’s market cap?
When is Pharma Mar SA’s upcoming earnings report date?
How were Pharma Mar SA’s earnings last quarter?
Is Pharma Mar SA overvalued?
Does Pharma Mar SA pay dividends?
What is Pharma Mar SA’s EPS estimate?
How many shares outstanding does Pharma Mar SA have?
What happened to Pharma Mar SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Pharma Mar SA?
What is the TipRanks Smart Score and how is it calculated?
Pharma Mar SA Stock Smart Score
Company Description
Pharma Mar SA
Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jose Maria Fernandez Sousa-Faro
- Employees
- 505
- Website
- www.pharmamar.com
- Address
- Avenida de los Reyes, 1, Madrid, 28770, ES
Pharma Mar SA (0RC6) Earnings & Revenues
0RC6 Earnings Call
Earnings Call SentimentPositive
The call communicated a strong set of financial results and clear strategic progress—notably robust revenue growth (+27% y/y), a material improvement in profitability (EBITDA ~5x; net income +187%), healthy cash generation (EUR 53m) and multiple regulatory/commercial advances for Zepzelca and other assets. Pipeline momentum (LAGOON, SaLuDo, PM54, PM534) and licensing deals (e.g., Merck for Japan) provide additional upside. Offsetting factors include a 12% decline in U.S. Zepzelca royalties driven by FX and competition, outstanding pricing/reimbursement negotiations in Europe, exposure to partner-controlled disclosures, generics risk for Yondelis, and planned increases in commercial spending. Overall, positive operational and financial trends materially outweigh the identified risks, though execution on European launches and partner dynamics will be key to sustaining momentum.
View all GB:0RC6 earnings summaries0RC6 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 15 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 0 | 0 | 12 |